Staten Biotechnology in $430m deal with Novo Nordisk
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Kurma Partners announce closing of Biofund III
/in News/by Thomas GabrielczykParis-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise 150m.
MEPs back 120bn budget for Horizon Europe
/in News/by Thomas GabrielczykThe European Parliament has voted to add 36.5bn to the budget of Horizon Europe (94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
New cheap CRS-blockers at the horizon
/in News/by Thomas GabrielczykCancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job […]
Oxford BioTherapeutics in $450 deal with Wuxi Biologics
/in News/by Thomas GabrielczykImmuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
Diabetes doubles risk for heart failure
/in News/by Thomas GabrielczykAn analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
AZ checkpoint blocker combo fails in head and neck cancer
/in News/by Thomas GabrielczykBritish drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
XyloCor Therapeutics bags US$17m in Series A financing
/in News/by Thomas GabrielczykLSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
BioFIT: innovation and investors
/in News/by Thomas GabrielczykFor two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number […]
Uncommon mutations affect breast cancer prognosis
/in News/by Thomas GabrielczykUncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.